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Background. HLA strongly influences human immunodeficiency virus type 1 (HIV-1) disease progression. A major contribu-
tory mechanism is via the particular HLA-presented HIV-1 epitopes that are recognized by CD8+ T-cells. Different populations vary
considerably in the HLA alleles expressed. We investigated the HLA-specific impact of the MRKAd5 HIV-1 Gag/Pol/Nef vaccine in a
subset of the infected Phambili cohort in whom the disease-susceptible HLA-B*58:02 is highly prevalent.
Methods. Viral loads, CD4+ T-cell counts, and enzyme-linked immunospot assay–determined anti-HIV-1 CD8+ T-cell respons-
es for a subset of infected antiretroviral-naive Phambili participants, selected according to sample availability, were analyzed.
Results. Among those expressing disease-susceptible HLA-B*58:02, vaccinees had a lower chronic viral set point than placebo
recipients (median, 7240 vs 122 500 copies/mL; P = .01), a 0.76 log10 lower longitudinal viremia level (P = .01), and slower progres-
sion to a CD4+ T-cell count of <350 cells/mm3 (P = .02). These differences were accompanied by a higher Gag-specific breadth (4.5
vs 1 responses; P = .04) and magnitude (2300 vs 70 spot-forming cells/106 peripheral blood mononuclear cells; P = .06) in vaccinees
versus placebo recipients.
Conclusions. In addition to the known enhancement of HIV-1 acquisition resulting from the MRKAd5 HIV-1 vaccine, these
findings in a nonrandomized subset of enrollees show an HLA-specific vaccine effect on the time to CD4+ T-cell count decline and
viremia level after infection and the potential for vaccines to differentially alter disease outcome according to population HLA
composition.
Clinical Trials Registration. NCT00413725, DOH-27-0207-1539.
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HLA class I alleles are an important predictor of disease course
in human immunodeficiency virus type 1 (HIV-1) infection [1].
In sub-Saharan Africa, HLA-B*57, HLA-B*58:01, and HLA-
B*81:01 are protective against disease progression, while
HLA-B*18:01 and HLA-B*58:02 are associated with rapid pro-
gression [2–4]. One contributory factor is the role of HLA mol-
ecules in presenting particular epitopes to induce CD8+ T-cell
responses against HIV-1. Gag-specific CD8+ T-cell responses
are associated with lower viremia levels and are dominant in
people with protective HLA alleles, such as HLA-B*57:03 [1,
5]. In contrast, disease-susceptible HLA alleles, such as HLA-
B*58:02, typically present relatively ineffective non-Gag re-
sponses [6] associated with high viral set points [5]. This
prompts the hypothesis that a successful vaccine might induce
Gag-specific responses in subjects who would not target this
protein in natural infection.
Two recent randomized efficacy trials of the MRKAd5 sub-
type B HIV-1 Gag/Pol/Nef T-cell vaccine provide a unique op-
portunity to address this hypothesis [7, 8]. The first study, Step,
was conducted in the Americas, Australia, and the Caribbean,
where HIV-1 subtype B predominates [7]. Both interim and fol-
low-up analyses reported vaccine-enhanced HIV-1 acquisition
[7, 9]. The second trial, Phambili, tested the efficacy of the
same vaccine in South Africa, where HIV-1 subtype C is en-
demic [8, 10]. Following Step discontinuation, Phambili was ter-
minated 9 months into the study, having enrolled 801 subjects
(27%) of the originally scheduled 3000 [10]. As in Step, the
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vaccine increased the risk of HIV-1 acquisition and did not re-
duce viremia levels in early infection [8, 10].
Post hoc Step studies, however, demonstrated lower viremia
levels in vaccinees with a greater breadth of Gag-specific CD8+
T-cell activity [11], consistent with the notion of Gag-specific ef-
ficacy, but also suggested the possibility of lower viral loads in
vaccinees expressing protective HLA alleles [12, 13]. To examine
this question in a population substantially dissimilar in the HLA
alleles expressed from that studied in Step, we here tested in the
South African Phambili cohort the hypothesis that the MRKAd5
HIV-1 vaccine might indeed have an HLA-specific effect.
Specifically, we hypothesized that subjects expressing HLA-
B*58:02, the most prevalent HLA-B allele in South Africans
[2, 5], might benefit from the MRKAd5 HIV-1 vaccine. The ra-
tionale was that the HLA-B*58:02–restricted CD8+ T-cell re-
sponse is solely Env specific and, therefore, associated with
poor immune control [5, 14]; HLA-B*58:02 indeed is strongly
associated with rapid HIV-1 disease progression in southern
Africa [2, 3, 6]. Hence, vaccine-mediated induction of Gag-
specific responses in subjects expressing HLA-B*58:02 would,
hypothetically, improve disease course in vaccinees who
subsequently became HIV-1 infected. HLA-B*18:01, also
strongly associated with rapid progression [2, 3], restricts a dom-
inant CD8+ T-cell epitope in Nef [5]. Although Nef-specific
CD8+ T-cell responses have also been associated with poor con-
trol of HIV-1 [5, 15–17], the immunodominance of the HLA-
B*18:01–restricted CD8+ T-cell response might be unaffected
by the MRKAd5 HIV-1 Gag/Pol/Nef vaccine.
We set out, therefore, to investigate the impact of the MRKAd5
HIV-1 vaccine in the Phambili trial, particularly on the HLA-
B*58:02–expressing individuals, to determine whether immune
control of HIV-1 was improved in vaccinees who subsequently
became infected. This study has limitations that we wish to high-
light, including postrandomization bias, sample selection bias,
and low subject numbers (see Discussion), but it provides poten-
tially important insights into HLA-dependent vaccine effects on
the postinfection disease course and immune response to HIV-1.
METHODS
Study Design
The Phambili Ancillary Study included 100 HIV-1–infected
Phambili participants (Supplementary Figure 1). Sixty of them,
Table 1. Baseline Characteristics of the 60 Infected Phambili Participants Studied in This Report
Characteristic Vaccine Placebo Total
Subjects 37 (62) 23 (38) 60 (100)
Age at enrollment, y 24 (21.5–28.5) 24 (22–32) 24 (22–29)
Sex
Female 21 (57) 18 (78) 39 (65)
Male 16 (43) 5 (22) 21 (35)
Study site
Soweto, Johannesburg 15 (41) 7 (30) 22 (37)
Emavundleni, Cape Town 8 (22) 6 (26) 14 (23)
CAPRISA, Klerksdorp 5 (14) 4 (17) 9 (15)
eThekwini, Durban 7 (19) 3 (13) 10 (17)
Medunsa, Polokwane 2 (5) 3 (13) 5 (8)
Time since diagnosis, mo.
Time point 1 2 (1–2.5) 2 (1–3) 2 (1–3)
Time point 2 12 (11–12) 11 (11–12) 12 (11–12)
Duration of follow-up data, time since diagnosis, mo. 17 (16–18) 17 (16–19) 17 (16–18)
Started ART 5 (14) 6 (26) 11 (18)
HLA typea
Protective
B*57:03 12 (32) 3 (13) 15 (25)
B*58:01 2 (5) 0 (0) 2 (3)
B*81:01 7 (19) 3 (13) 10 (17)
Disease susceptible 4 (11) 0 (0) 4 (7)
B*18:01 0 (0) 1 (4) 1 (2)
B*58:02 7 (19) 7 (30) 14 (23)
Neither protective nor disease-susceptible 18 (49) 13 (57) 31 (52)
Early viral set point,b copies/mL 41 850 (3 675–234 075) 88 500 (11 485–238 500) 71 700 (6 475–238 500)
Data are no. (%) of subjects or median value (interquartile range). There were no significant differences between vaccine and placebo groups for any of the characteristics.
Abbreviation: ART, antiretroviral therapy.
a HLA types were grouped by their association with disease progression, as specified in “Methods” section.
b Defined as the median of human immunodeficiency virus type 1 load measurements 2–3 months after diagnosis, as specified in “Methods” section.












for whom HLA types, peripheral blood mononuclear cell
(PBMC), viral load, and CD4+ T-cell count data were available,
compose the focus of this report (Table 1). For the remaining
40 individuals, no PBMC were available to assess CD8+ T-cell re-
sponses, and thus only selected viral load and CD4+ T-cell count
data were included in additional analyses; material for HLA typ-
ing was available for 25 participants. Subjects were categorized as
having protective HLA-B expression (HLA-B*57:02/57:03/58:01/
81:01); disease-susceptible HLA-B expression (HLA-B*18:01/
58:02), and neither protective nor disease-susceptible HLA-B ex-
pression (eg, HLA-B*42:01/44:03) [2, 3]. For the most prevalent
HLA-B allele, HLA-B*58:02 (phenotypic frequency, 23%), there
were sufficient subject numbers to compare vaccinees (n = 7) to
placebo recipients (n = 7). All participants provided written
informed consent; ethics committee at each clinical site and the
University of Oxford approved the study.
To identify associations between HLA expression and recog-
nition of HIV-1–specific peptides, we used enzyme-linked im-
munospot (ELISPOT) data from 1031 untreated subjects with
chronic natural HIV-1 infection from the previously described
Sinikithemba (enrolled in 2003–2008) and Gateway (enrolled in
2012–2013) cohorts in Durban, South Africa [5, 18]. The medi-
an viral load in these subjects was 25 700 copies/mL (range,
3690–119 000 copies/mL), and the median CD4+ T-cell count
was 404 cells/mm3 (range, 273–549 cells/mm3). PBMCs from
each individual were screened with a panel of peptides spanning
the entire C-clade 2001 consensus sequence [5] and analyzed
(Supplementary Materials). To compare the CD8+ T-cell re-
sponses in the HLA-B*58:02–positive South African Phambili
subjects to those in HLA-B*58:02–positive South African sub-
jects naturally infected with HIV-1, we used ELISPOT data
from 66 HLA-B*58:02–positive subjects from the Sinikithemba
cohort because individuals in both groups would have had a
similar geographical location, genetic background, timing of in-
fection, and infection with similar/related viral species (Supple-
mentary Table 3).
Interferon γ (IFN-γ) ELISPOT Assays
Blinded to the vaccine/placebo treatment assignments, we
screened PBMCs from the 60 subjects with available cells to
quantify IFN-γ ELISPOT responses to pools (n = 36) of overlap-
ping peptides spanning the entire C-clade HIV-1 proteome,
based on the 2001 C-clade consensus [5]. For each subject,
cells obtained 2 and 12 months after diagnosis (Table 1) were
tested [19, 20]. Responses were divided into 4 groups: specific
to Gag, specific to Pol, specific to Nef, or specific to other
(Env, Tat, Rev, Vpu, Vpr, and Vif ) proteins. Breadth was de-
fined as the number of pools testing positive (>50 spot-forming
cells [SFCs]/106 PBMCs, after background subtraction).
Statistical Analysis
Baseline characteristics (Table 1) between vaccine and placebo
recipients were analyzed using the Mann–Whitney U test or the
Fisher exact test (Prism v5.0c). Only pre-ART viral loads were
used. Early viral set point was defined as the geometric mean of
HIV-1 load measurements 2–3 months after diagnosis [7, 10].
To determine the viral set point more accurately, we also de-
fined the long-term chronic set point as the median of all
pre-ART viral loads available as (1) including the diagnostic
(acute) measurement, (2) excluding the diagnostic measure-
ment, (3) including all measurements from >2 weeks after diag-
nosis, (4) including all measurements from >1 month after
diagnosis, or (5) including all measurements from >3 months
after diagnosis. Chronic set points were very similar irrespective
of the definition, and results using definition 4 are reported here
because this may most accurately reflect the beginning of the
chronic phase [21, 22]. Set-point differences between vaccinees
and placebo recipients were analyzed using the Mann–Whitney
U test (Prism v5.0c).
Linear mixed-effects models were constructed to investigate
the effects of vaccination, sex, age, anti–adenovirus serotype 5
(Ad5) antibody levels, and herpes simplex virus type 2 (HSV-
2) serostatus on longitudinal viremia levels. Random intercept
models were constructed with the grouping by participant iden-
tifier in R, using the lme4 library [23];P values were obtained by
comparing models with and those without vaccination as a
fixed effect (analysis of variance [ANOVA]) [24].
The log-rank test (Prism v5.0c) and univariate Cox regression
models (SPSS v22.0) were used to compare time to disease pro-
gression between vaccine and placebo groups, defined by a CD4+
T-cell count of <350 cells/mm3, the World Health Organization’s
CD4+ T-cell count criterion for ART initiation [25]. Only pre-
ART CD4+ T-cell counts were included; the impact of sex, age,
Ad5 antibody levels, and HSV-2 serostatus was checked.
Differences in ELISPOT responses between vaccinees and
placebo recipients were analyzed in Prism v5.0c by the Mann–
Whitney U test (2-group analyses) or the Kruskal–Wallis test
(3-group analyses).
To identify associations between expression of HLA alleles and
recognition of HIV-1–specific peptides, we used a decision tree
based on the Fisher exact test (Supplementary Materials) [26].
RESULTS
HLA-Independent Vaccine Effects
We first compared the baseline characteristics between vaccine
and placebo recipients in the selected subgroup of 60 subjects
for whom PBMCs were available to test the impact of the
MRKAd5 HIV-1 vaccine on postinfection CD8+ T-cell activity.
These showed no significant differences in age, sex, HLA-B ge-
notype, or early viral set point (Table 1). As previously reported
[7, 10, 27], median early viral set point did not differ signifi-
cantly between vaccine and placebo recipients among these
60 patients (41 850 copies/mL [interquartile range {IQR},
3657–234 075 copies/mL] vs 88 500 copies/mL [IQR, 11 485–
238 500 copies/mL], P = .34; Table 1). We observed a trend












toward a lower median chronic viral set point in vaccinees in the
60 subjects (12 055 copies/mL [IQR, 3805–137 500 copies/mL]
vs 103 600 copies/mL [IQR, 9190–141 800 copies/mL], P = .055;
Figure 1A). However, this difference did not reach statistical sig-
nificance, even when all of the viral load data were analyzed
using a linear mixed-effects model (P = .058; Figure 1B). It is
important to take note of the fact that 12 vaccinees expressed
protective alleles (HLA-B*57/58:01/81:01), compared with 3
placebo recipients, although this also did not reach statistical
significance (P = .13). Additionally, there was no significant dif-
ference in time to disease progression (ie, time to a CD4+ T-cell
count of <350cells/mm3) between vaccine and placebo groups
(P = .25; Figure 1C).
Examining the impact of the MRKAd5 HIV-1 vaccine on
CD8+ T-cell IFN-γ responses after infection in Phambili sub-
jects with available PBMCs, we observed that vaccinees had sig-
nificantly higher Gag-specific breadth and magnitude than
placebo recipients (P = .03 and P = .02, respectively, 2 months
after diagnosis; and P = .05 and P = .02, respectively, 12 months
after diagnosis; Figure 1D). These assays were undertaken blind-
ed to the subjects’ vaccination assignments. There was no differ-
ence between the 2 groups in the responses toward proteins not
included in the vaccine (Env, Vif, Vpr, Vpu, Tat, and Rev).
However, there was no significant difference in the Pol- or
Nef-specific responses between vaccine and placebo recipients
either, despite pol/nef inclusion in the vaccine.
HLA-Specific Vaccine Effects on Viral Load and CD4+ T-Cell Counts:
Protective HLA Alleles
To investigate whether these vaccine-mediated effects on the
CD8+ T-cell responses were associated with HLA-specific im-
mune control, as observed for protective HLA alleles in the
Step trial [12], we first compared chronic viral set points and
time to a CD4+ T-cell count of <350 cells/mm3 in the subset
of infected Phambili subjects expressing any of the protective
alleles HLA-B*57/58:01/81:01 (Table 2). Although subject
numbers provided limited power (3 placebo recipients vs 12
vaccinees expressed HLA-B*57/58:01/81:01), there was evi-
dence of vaccine-mediated immune protection through these
HLA alleles (Figure 2A and 2B), with a significantly more-
rapid time to disease progression (ie, a CD4+ T-cell count
of <350 cells/mm3) in placebo recipients (P = .009). Placebo/
vaccine treatment assignment was the only significant contrib-
utor to this difference in a univariate analysis that included sex,
Figure 1. Longitudinal viremia levels, CD4+ T-cell counts, and CD8+ T-cell responses in the 60 infected vaccinees and placebo recipients, irrespective of HLA. A, Chronic viral
set point (defined for each individual as the median of all measurements from >3 months after diagnosis). Each patient’s set point is shown as a circle (vaccine recipients) or
triangle (placebo recipients), and horizontal lines and numbers denote median values. Statistical analysis was performed by the Mann–Whitney U test. B, Examination of the
effect of vaccination on longitudinal viremia levels before antiretroviral therapy initiation. The slopes (thick lines) generated from a linear mixed-effects model are plotted on top
of data points and viral load trajectories for individual patients (thin lines). Statistical analysis was performed by analysis of variance. C, Kaplan–Meier curves showing time to
reach a CD4+ T-cell count of <350 cells/mm3 in vaccinees and placebo recipients. Statistical analysis was performed by the log-rank test. D, Breadth and magnitude of CD8+ T-cell
responses at the second time point in vaccinees and placebo recipients. In Tukey box plots, horizontal lines indicate median values, boxes show interquartile ranges, and whiskers
show minimum and maximum values. Statistical analysis was performed by the Mann–Whitney U test. The column termed “Total” shows the combined values of responses to all
proteins; the column termed “Other” includes responses to Env, Rev, Tat, Vpu, Vif, and Vpr. Abbreviations: IFN-γ, interferon γ; PBMC, peripheral blood mononuclear cell; SFC, spot-
forming cells.












age, Ad5 antibody levels, and HSV-2 status (Supplementary
Table 1).
HLA-Specific Vaccine Effects on Viral Load and CD4+ T-Cell Counts:
Disease-Susceptible HLA Alleles
With respect to the disease-susceptible HLA alleles, HLA-
B*18:01 and HLA-B*58:02, none of the vaccinees with available
PBMCs and HLA data expressed HLA-B*18:01, and analyses
were limited to the HLA-B*58:02–positive subjects (7 vaccinees
and 7 placebo recipients; Table 2). Median chronic viral
set point was significantly lower in HLA-B*58:02–positive
vaccinees (7240 copies/mL [IQR, 4090–63 000 copies/mL]
vs 122 500 copies/mL [IQR, 103 600–677 500 copies/mL];
P = .01; Figure 2C). This difference was especially clear when
all pre-ART longitudinal data points were interrogated using
a mixed-effects model (P = .01; Figure 2C). These data show
that vaccination in the HLA-B*58:02–positive subjects on aver-
age resulted in a 0.76 log10 reduction in chronic viral set point
and that no other factors (sex, age, Ad5 antibody levels, and
HSV-2 serostatus) had a significant influence. The viral load
differences between vaccinees and placebo recipients remained
significant when the 3 additional HLA-B*58:02–positive sub-
jects were added from the Phambili participants with deter-
mined HLA types but unavailable PBMCs (P = .03, by the
Mann–Whitney U test; P = .03, by an ANOVA mixed-effects
model).
Progression to a CD4+ T-cell count of <350 cells/mm3 was
also significantly slower in HLA-B*58:02–positive vaccinees as
compared to placebo recipients (P = .02, by the log-rank test
[Figure 2D]; hazard ratio [HR], 0.22 [95% CI, .05–.91; P = .04,
by a Cox regression model; Supplementary Table 2]). Again, the
only significant contributor to this difference was placebo /vac-
cine treatment assignment, and the difference between vaccine
and placebo recipients remained significant with addition of the
3 HLA-B*58:02–positive subjects with determined HLA types
but unavailable PBMCs (P = .03, by the log-rank test; HR,
0.29 [95% CI, .06–.99; P = .04, by a Cox regression model;
Supplementary Table 2]). Finally, among the HLA-B*58:02–
positive subjects studied, one individual also expressed
protective HLA-B*58:01, and exclusion of this subject did not
materially alter the findings described (viral set point difference,
P = .01; time to a CD4+ T-cell count of <350 cells/mm3, P = .04).
Similarly, no significant difference was observed with respect to
HLA-C alleles expressed among the HLA-B*58:02–positive sub-
jects studied; in each case, HLA-C*06:02 was expressed in linkage
disequilibrium with HLA-B*58:02.
HLA-Specific Vaccine Effects on Viral Load and CD4+ T-Cell Counts:
Neither Protective nor Disease-Susceptible HLA Alleles
Analysis of the subjects expressing neither protective nor
disease-susceptible alleles showed no differences between
vaccine and placebo groups in chronic viral set points or
time to a CD4+ T-cell count of <350 cells/mm3 (Figure 3A
and 3B). Representative observations are illustrated by the
HLA-B*44:03–expressing subjects (6 in each group; Figure 3C
and 3D).
HLA-Specific Vaccine Effects on Anti–HIV-1 CD8+ T-Cell Responses
To investigate whether the apparent effects on reduced viral
load and slower time to a CD4+ T-cell count of <350 cells/
mm3 observed might be related to HLA-specific induction of
altered CD8+ T-cell responses in the vaccinees versus placebo
Table 2. Demographic Characteristics Stratified by HLA Group
Characteristic
Protective HLA




Vaccine (n = 12) Placebo (n = 3) Vaccine (n = 18) Placebo (n = 13) Vaccine (n = 7) Placebo (n = 7)
Age at enrollment, y 25.5 (22.5–30.5) 32 (22–32) 22.5 (21.5–30.5) 23 (22–26) 22 (21–27) 26 (21–34)
Sex
Female 7 (58) 3 (100) 9 (50) 10 (77) 5 (71) 5 (71)
Male 5 (42) 0 (0) 9 (50) 3 (23) 2 (29) 2 (29)
Circumcision statusa
Circumcised 2 (40) . . . 5 (56) 1 (33) 0 (0) 0 (0)
Uncircumcised 3 (60) . . . 4 (44) 2 (67) 2 (100) 2 (100)
Adenovirus 5 statusb
Seropositive 9 (75) 2 (67) 17 (94) 12 (92) 6 (86) 4 (57)
Seronegative 3 (25) 1 (33) 1 (6) 1 (8) 1 (14) 3 (43)
HSV-2 status at enrollment
Positive 9 (75) 2 (67) 10 (56) 5 (38) 2 (29) 5 (71)
Negative 3 (25) 1 (33) 8 (44) 8 (62) 5 (71) 2 (29)
Data are no. (%) of subjects or median value (interquartile range). There were no significant differences between vaccine and placebo groups within each HLA subset for any characteristic.
Abbreviation: HSV-2, herpes simplex virus type 2.
a Data are for men circumcised at baseline or during study but before infection and those uncircumcised throughout study or before infection.
b Seropositivity was defined as a titer of >18, and seronegativity was defined as a titer of ≤18.












recipients, we first analyzed these in HLA-B*58:02–positive
study subjects. Median Gag-specific breadth was 4.5-fold higher
in vaccinees (4.5 responses [IQR, 2–5 responses] vs 1 response
[IQR, 0–3 responses]; P = .04; Figure 4A), and the median Gag-
specific magnitude was 32-fold higher (2300 SFCs/106 PBMCs
[median, 603–6105 SFCs/106 PBMCs] vs 70 SFCs/106 PBMCs
[0–1520 SFCs/106 PBMCs]; P = .06; Figure 4A). Additionally,
we compared the CD8+ T-cell responses in the Phambili sub-
jects to those of HLA-B*58:02–positive unvaccinated individu-
als with natural chronic HIV-1 C-clade infection (n = 66;
Figure 4A), most of whom (79%) were females recruited in
South Africa (Supplementary Table 3). Here alsowe observed that
the Phambili HLA-B*58:02–positive vaccinees had a significantly
higher Gag-specific breadth as compared to non-Phambili in-
fected subjects (P = .04), while the difference between HLA-
B*58:02–positive placebo recipients and non-Phambili subjects
was not significant. The median Gag-specific magnitude was
>2-fold higher in HLA-B*58:02–positive vaccinees as compared
to non-Phambili HLA-B*58:02–positive subjects (1100 SFCs/106
PBMCs [IQR, 255–2050 SFCs/106 PBMCs]; P = .2). No signifi-
cant associations were found between Gag-specific breadth/
magnitude and viral loads or CD4+ T-cell count in HLA-
B*58:02–positive vaccinees (Supplementary Figure 2).
In contrast, in subjects expressing neither protective nor dis-
ease-susceptible alleles, the difference between the groups in
median Gag-specific breadth and magnitude was more modest
(2 responses [IQR, 1.5–3 responses] vs 1 response [IQR, 0–2 re-
sponses; P = .09]; and 529 SFCs/106 PBMCs [IQR, 166–2163
SFCs/106 PBMCs] vs 180 SFCs/106 PBMCs [IQR, 0–377 SFCs/
106 PBMCs; P = .06]; Figure 4B). No significant differences were
observed in Gag breadth and magnitude in the subjects express-
ing protective HLA (Figure 4C).
Although the MRKAd5 HIV-1 Gag/Pol/Nef vaccine ap-
peared to boost Gag-specific responses overall in vaccinees
Figure 2. Chronic viral set point and CD4+ T-cell counts in infected Phambili subjects expressing protective HLA-B*57/58:01/81:01 or disease-susceptible HLA-B*58:02
alleles. A–C, Data for the participants expressing protective alleles (12 vaccinees and 3 placebo recipients). D–F, Data for the participants expressing HLA-B*58:02 (7 vaccinees
and 7 placebo recipients). A and C, Chronic viral set point (defined for each individual as the median of all measurements from >3 months after diagnosis) is shown at left. Each
patient’s set point is shown as circles (vaccine recipients) or triangles (placebo recipients). Horizontal lines and numbers denote median values for vaccine and placebo groups.
Statistical analysis was performed by the Mann–Whitney U test. Examination of the effect of vaccination on longitudinal viral load values before antiretroviral therapy initiation
is shown at right. The slopes (thick lines) generated from a linear mixed-effects model are plotted on top of data points and viral load trajectories (thin lines) for individual
patients. Statistical analysis was performed by analysis of variance. B and D, Kaplan–Meier curves showing time to reach a CD4+ T-cell count of <350 cells/mm3 in vaccinees
and placebo recipients. Statistical analysis was performed by the log-rank test.












within the 60 subjects studied here (Figure 1D), there were no
significant differences for the CD8+ T-cell responses toward Pol,
Nef, or Env, Vif, Vpr, Vpu, Tat, or Rev in the 3 HLA groups
(Figure 4). However, of note, in addition to having a signifi-
cantly broader Gag-specific response, HLA-B*58:02–positive
vaccinees tended to have a narrower Nef-specific response
(P = .06; Figure 4A). The potential relevance of this is discussed
below.
Together, our findings support the original hypothesis that
the MRKAd5 HIV-1 vaccine could improve disease outcome
by boosting beneficial Gag-specific responses [5] in HLA-
B*58:02–positive individuals who, during naturally acquired in-
fection, do not generate HLA-B*58:02–restricted Gag responses
but produce predominantly Env-specific ineffective responses
(Figure 5).
DISCUSSION
This study set out to investigate whether the HLA-specific vac-
cine effects suggested in the Step trial [12, 13, 28] could be dem-
onstrated in the ethnically dissimilar Phambili cohort. Half of
the Step trial participants who subsequently became infected
were white, whereas none of the Phambili cohort was white. Ex-
pression of HLA class I molecules, such as HLA-B*42:01, HLA-
B*58:02, and HLA-B*81:01, for example, is observed in 0% of
white individuals [29] and in 20%, 23%, and 10%, respectively,
of Black South Africans [2, 5]. The principal finding in the
current study is an HLA-specific vaccine effect in subjects ex-
pressing the disease-susceptible HLA-B*58:02. HLA-B*58:02–
positive vaccinees had a significantly lower viral set point and
progressed more slowly to a CD4+ T-cell count of <350 cells/
mm3, compared with HLA-matched placebo recipients. This
Figure 3. Chronic viral set point and CD4+ T-cell counts in the infected Phambili subjects expressing neither protective nor disease-susceptible HLA alleles. A and B, Data for
the participants expressing neither protective nor disease-susceptible alleles overall (18 vaccinees and 13 placebo recipients). C and D, Example of a subset of the subjects from
panels A and B who express HLA-B*44:03 and for whom there were sufficient subject numbers to compare vaccine (n = 6) and placebo (n = 6) groups. A and C, Chronic viral set
point (defined for each individual as the median of all measurements from >3 months after diagnosis) is shown at left. Each patient’s set point is shown as a circle (vaccine
recipients) or triangle (placebo recipients), and horizontal lines and numbers denote median values for vaccine and placebo groups. Statistical analysis was performed by the
Mann–Whitney U test. Examination of the effect of vaccination on longitudinal viral load values before antiretroviral therapy initiation is shown at right. The slopes (thick lines)
generated from a linear mixed-effects model are plotted on top of the data points and viral load trajectories (thin lines) for individual patients. Statistical analysis was performed
by analysis of variance. B and D, Kaplan–Meier curves showing the time to reach a CD4+ T-cell count of <350 cells/mm3 in vaccinees and placebo recipients. Statistical analysis
was performed by the log-rank test. Abbreviation: NS, not significant.












result was associated with an increased breadth and magnitude
of Gag-specific CD8+ T-cell responses in vaccinees expressing
HLA-B*58:02. In contrast, in Phambili subjects expressing nei-
ther protective nor disease-susceptible alleles, these vaccine ef-
fects were not observed.
The described HLA-specific vaccine effect was suggested in
the Step study in relation to the protective HLA-B*27:05/
B*57:01/B*58:01 [12, 13, 28]. Analysis here also showed a 1.3
log10 lower viral load and significantly slower progression
to CD4+ T-cell count of <350 cells/mm3 (P = .009) in vaccinees
expressing protective HLA-B*57:02/57:03/58:01/81:01 [2, 3],
compared with HLA-matched placebo recipients. However,
these analyses were limited by numbers (only 3 placebo
recipients).
Our finding of reduced viral load and slower time to a CD4+
T-cell count of <350 cells/mm3 in HLA-B*58:02–positive vacci-
nees is significant. First, viral load in natural infection is 4.9–5.2
log10 copies/mL [6, 30], similar to that in the HLA-B*58:02–
positive placebo recipients here (5.1 log10 copies/mL), corre-
sponding to rapid progression and a high risk of further
transmissions [2–4, 31]. The 17-fold reduction in viral set point
in HLA-B*58:02–positive vaccinees observed here equates to a
>5-year AIDS-free period without ART and a >2-fold reduction
in onward transmission risk [31]. Second, HLA-B*58:02 is highly
prevalent in sub-Saharan Africa (20%–25% of South Africans)
[2, 5]. Thus, a vaccine effect on postinfection disease progression
in subjects expressing protective HLA-B*57/58:01/81:01 (24% of
South Africans [2, 5]) and in those expressing HLA-B*58:02
would favorably affect disease course in approximately half of
the population.
The HLA-B*58:02–specific effect observed supports the orig-
inal hypothesis. HLA-B*58:02–restricted CD8+ T-cell responses
are almost exclusively directed against Env, which is associated
with a high viral load [5] (Figure 5). The MRKAd5 HIV-1
Figure 4. CD8+ T-cell responses in the infected Phambili subjects expressing disease-susceptible HLA-B*58:02 or those expressing neither protective nor disease-susceptible
alleles or those expressing protective HLA alleles. A, Breadth and magnitude of CD8+ T-cell responses at the second time point in HLA-B*58:02–positive vaccinees, placebo
recipients, and C clade chronically infected unvaccinated B*58:02-positive individuals. B, Breadth and magnitude of CD8+ T-cell responses at the second time point in vaccinees
and placebo recipients expressing neither protective nor disease-susceptible HLA-B alleles. C, Breadth and magnitude of CD8+ T-cell responses at the second time point in
vaccinees and placebo recipients expressing protective HLA-B alleles. In Tukey box plots, horizontal lines indicate median values, boxes show interquartile ranges, and whiskers
show minimum and maximum values. Statistical analysis was performed by the Kruskal–Wallis and Mann–Whitney U tests. The column termed “Total” shows the combined
values of responses to all proteins; the column termed “Other” includes responses to Env, Rev, Tat, Vpu, Vif, and Vpr. Abbreviations: IFN-γ, interferon γ; NS, not significant;
PBMC, peripheral blood mononuclear cell; SFC, spot-forming cells.












vaccine might therefore be expected to improve outcome by
boosting beneficial Gag responses [5, 11]. A 70-fold higher mag-
nitude and a 4–5-fold greater breadth of Gag-specific responses
were observed in HLA-B*58:02–positive vaccine recipients, but
the necessary samples were unavailable to determine whether
these were restricted by HLA-B*58:02 or by other HLA alleles
expressed by these subjects.
Although previous studies have shown a correlation between
increasing Gag breadth and decreasing viral load [5, 15, 32, 33],
including in vaccinees in the Step study [28], this was not
observed here (Supplementary Figures 2 and 3). In part this is
due to our small study numbers. In addition, Gag-specific
responses are not equally potent. For example, p24-specific re-
sponses are associated with better viremic control than p17- or
p15-specific responses [34]. However, in this study the design
of the Gag peptide pools made these subanalyses not possible.
Furthermore, sample nonavailability prevented the HLA restric-
tion of the CD8+ T-cell responses in the vaccinees to be deter-
mined. In large cohort studies, on average, Gag-specific breadth
is associated with a lower viral load, but in small studies the var-
iation between the different Gag and non-Gag responses will
strongly influence these analyses. Furthermore, the vaccine-
mediated increase in Gag breadth may be associated with
changes in the non–Gag-specific responses. On average Nef-
specific and Env-specific responses are associated with higher
viral loads [5, 15]. In our study, Nef-specific breadth in infected
HLA-B*58:02–positive vaccinees was 4-fold lower than in HLA-
B*58:02–positive placebo recipients (P = .06).Nef-specific breath
has been consistently shown in previous studies to be associated
with higher viral loads and the same observation is made here
(Supplementary Figures 2 and 3). Thus, the finding of a lower
viral loads in B*58:02-positive subjects with both higher Gag-
specific and lower Nef-specific responses may be the result of
a combination of these effects.
The limitations of this study include small subject numbers,
the potential for postrandomization bias [35], and the caveats
that apply to any post hoc analysis. To address the possibility
that the differences in postinfection outcomes were caused by
the differences in characteristics associated with infection risk,
rather than by vaccination, we investigated the impact of HLA
on HIV-1 acquisition among 329 (of 801) Phambili subjects
with available HLA data. There was no such influence in either
vaccine or placebo recipients. This suggests that HLA does not
confound the association of vaccination status with disease pro-
gression [36] and is consistent with ample data showing the im-
pact of HLA on disease progression but not on HIV-1 acquisition
[1, 37]. Skewing could have been introduced by unintended sam-
ple selection bias: PBMCs were only available for 60 of the 100
HIV-1–infected subjects, and the 40 subjects with unavailable
samples and thus unknown CD8+ T-cell responses showed a fast-
er time to a CD4+ T-cell count of <350 cells/mm3. However, the
absence of data on the CD8+ T-cell response in this group of 40
more-rapidly progressing subjects does not alter the validity of
the finding in relation to the 60 we were able to study.
Finally, although low CD4+ T-cell count and high viral load
are, separately, strongly correlated with an increased risk of
opportunistic infections and mortality [38, 39], these measures
do not necessarily equate with disease [40]. However, the
Figure 5. HLA-dependent differential immunodominance hierarchy of CD8+ T-cell responses in chronically C clade–infected, antiretroviral-naive, South African adults. CD8+
T-cell immunodominance hierarchy in subjects in the 3 HLA groups (allele frequency ≥5%), expressing protective HLA, neither protective nor disease-susceptible HLA, and
disease-susceptible HLA. Targeting frequency denotes the percentage of subjects making detectable responses in interferon γ enzyme-linked immunospot assays to the named
human immunodeficiency virus type 1 peptide. Numbers on the x-axis refer to the particular overlapping peptide (of 410 spanning the C clade proteome) to which a response
was detected. The x in each column denotes the median viral load of responders to that peptide.












observation of progression to a CD4+ T-cell count of <350 cells/
mm3 within 6 months of infection in >80% of the HLA-
B*58:02–positive placebo recipients, together with a viral set
point of 5.1 log10 copies/mL in these subjects, is consistent
with rapid progression observed in natural infection in HLA-
B*58:02–positive individuals [6, 30]. The 1.3 log10 lower viral
set point in HLA-B*58:02–positive vaccinees and the inability
of >50% to meet the CD4+ T-cell count criteria for ART initi-
ation by 600 days after infection are consistent with vaccine-
mediated protection against rapid progression.
In conclusion, although the MRKAd5 HIV-1 Gag/Pol/Nef
vaccine increased the infection risk among vaccine recipients
in the Step and Phambili trials [7, 8, 10], these data suggest its
potential role as a therapeutic vaccine operating in an HLA-
specific manner, with the capacity to benefit individuals
expressing disease-susceptible alleles. Even in ART recipients,
CD8+ T cells may contribute to suppression of viremia [41],
and so-called shock and kill cure strategies [42] may likely re-
quire effective anti–HIV-1 CD8+ T-cell activity to achieve success-
ful eradication of viral reservoirs [43]. Any theoretical increased
risk of HIV-1 infection resulting from adenoviral-based vaccines
in subjects already infected with HIV-1 would be low as compared
to the potential therapeutic benefit of inducing an effective anti–
HIV-1 T-cell response. These studies indicate that the dramatic
differences in HLA composition between distinct populations
may contribute to variation in vaccine efficacy.
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